Center for Research in Security Prices, LLC

Abridge launches research collaborative with Epic, Stanford to study AI's impact on clinician experience, patient experience, healthcare costs, outcomes, and health equity. Epic faces antitrust lawsuit from Particle Health over data market dominance. Micky Tripathi, federal health IT official, oversees HHS's AI strategy and data standards. Stanford's James Zou discusses limited reimbursement for FDA-authorized AI medical devices. MedStar's Raj Ratwani proposes a certification process for AI systems with local testing support. Pitchbook report indicates generative AI's limited impact in clinical trials due to regulatory hurdles. Senate Dems introduce Health Infrastructure Security and Accountability Act to set minimum cyber standards for healthcare entities.

The Inflation Reduction Act's price controls on drugs threaten small biotech firms, stifling medical innovation. Instead of targeting PBMs, the Act imposes price controls on drug makers, risking future breakthroughs. Congress should reform PBM practices for more effective drug cost reduction.

Cancer death rates have dropped 25% since 2000, with stage 4 now survivable for many. Breakthrough therapies, not just doctors, are credited. The Inflation Reduction Act's price controls threaten to reduce biotech R&D, leading to fewer new drugs and lost life-years. Companies like Novartis and Astellas are already cutting research due to these controls.

Two-thirds of incarcerated Americans struggle with substance abuse, often opioid addiction. New research finds less than half of U.S. jails provide access to medications for opioid use disorder, and even fewer make them available to all inmates.

Black patients with triple-negative breast cancer receive immunotherapy at lower rates than White patients, with socioeconomic factors identified as barriers, according to a study presented at the 2024 AACR Conference. Despite lower immunotherapy access, Black patients showed similar survival rates when treated, highlighting the potential of immunotherapy to mitigate racial disparities in outcomes.

VerImmune Inc. secures $4.5 million in Pre-Series A funding led by Beiley Biofund, with participation from Dr. John Ballantyne and others. The funds will advance the ViP-based therapeutics platform, including the lead product VERI-101, a first-in-class cancer immunotherapy. The company also adds Dr. Che Hsu and Dr. Marta New to its Board of Directors.

Senator Bernie Sanders will lead a Senate HELP Committee hearing on Ozempic and Wegovy prices, focusing on price controls despite R&D costs and potential harm to medical innovation. The hearing aims to address the high cost of these diabetes medicines, but critics argue it overlooks the significant R&D investments required and the broader implications for future drug development.

VerImmune Inc. secures $4.5 million in Pre-Series A funding led by Beiley Biofund. The company plans to advance its ViP-based therapeutics, including the lead product VERI-101, a cancer immunotherapy. New board members Dr. Che Hsu and Dr. Marta New bring extensive experience in novel modalities.